title: Indirect antitumor effects of mammalian target of rapamycin inhibitors against Kaposi sarcoma in transplant patients.
authors.forename: Patrizia
authors.initials: P
authors.lastname: Barozzi
authors.forename: Giovanni
authors.initials: G
authors.lastname: Riva
authors.forename: Daniela
authors.initials: D
authors.lastname: Vallerini
authors.forename: Raffaella
authors.initials: R
authors.lastname: Bosco
authors.forename: Chiara
authors.initials: C
authors.lastname: Quadrelli
authors.forename: Eleonora
authors.initials: E
authors.lastname: Zanetti
authors.forename: Leonardo
authors.initials: L
authors.lastname: Potenza
authors.forename: Fabio
authors.initials: F
authors.lastname: Forghieri
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Torelli
authors.forename: Mario
authors.initials: M
authors.lastname: Luppi
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D005871:Castleman Disease / Q000209:etiology / Q000276:immunology; D019288:Herpesvirus 8, Human / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology; D054685:Lymphoma, Primary Effusion / Q000209:etiology / Q000276:immunology; D011494:Protein Kinases / Q000187:drug effects*; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology / Q000821:virology; D020123:Sirolimus / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology; D058570:TOR Serine-Threonine Kinases; D014181:Transplantation Immunology
chemical_list: D000903:Antibiotics, Antineoplastic; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus